Premium
Alveolar rhabdomyosarcoma after treatment of osteosarcoma
Author(s) -
Kasahara Yasushi,
Iwabuchi Haruko,
Takachi Takayuki,
Hosokai Ryosuke,
Yoshida Sakiko,
Imamura Masaru,
Watanabe Akihiro,
Umezu Hajime,
Hotta Tetsuo,
Ogose Akira,
Imai Chihaya
Publication year - 2013
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.12070
Subject(s) - medicine , osteosarcoma , rhabdomyosarcoma , histopathology , sarcoma , alveolar rhabdomyosarcoma , chemotherapy , radiation therapy , genetic predisposition , doxorubicin , oncology , pediatric cancer , germline , cancer , pathology , disease , gene , genetics , biology
Secondary rhabdomyosarcoma ( RMS ) after treatment of osteosarcoma ( OS ) is rare. Reported here is the case of a metachronous RMS in the nasal cavity, developing 12 years after successful treatment of non‐metastatic OS . The patient was diagnosed as having OS of the femur at 2 years of age. Chemotherapy for OS included doxorubicin (cumulative dose, 488 mg/m 2 ). No radiotherapy was given. There was no family history suggestive of cancer predisposition syndrome. At 14 years of age, alveolar RMS was diagnosed on histopathology. PAX 3‐ FKHR fusion transcripts were detected on reverse transcription–polymerase chain reaction. Germline TP 53 mutation was not seen on standard DNA sequencing. The occurrence of secondary sarcomas, in the C hildren's C ancer S urvivor study conducted in N orth A merica, has been associated with high cumulative doses of anthracyclines, which may also have played a role in the development of RMS in the present case. In the future, novel molecular technologies might uncover genetic cancer predisposition in patients with metachronous cancers.